CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics

Debarati Ghosh,
Prabhadevi Venkataramani,
Saikat NandiEmail author and
Sonali BhattacharjeeEmail author View ORCID ID profile

Cancer Cell International201919:12

https://doi.org/10.1186/s12935-019-0726-0

Received: 13 November 2018
Accepted: 2 January 2019
Published: 8 January 2019

Abstract

Genome editing allows for the precise manipulation of DNA sequences in a cell making this technology essential for understanding gene function. CRISPR/Cas9 is a targeted genome-editing platform derived from bacterial adaptive immune system and has been repurposed into a genome-editing tool. The RNA-guided DNA endonuclease, Cas9 can be easily programmed to target new sites by altering its guide RNA sequence, making this technology easier, more efficient, scalable and an indispensable tool in biological research. This technology has helped genetically engineer animal models to understand disease mechanisms and elucidate molecular details that can be exploited for improved therapeutic outcomes. In this review, we describe the CRISPR–Cas9 gene-editing mechanism, CRISPR-screening methods, therapeutic targeting of CRISPR in animal models and in cancer immunotherapy. We also discuss the ongoing clinical trials using this tool, limitations of this tool that might impede the clinical applicability of CRISPR–Cas9 and future directions for developing effective CRISPR–Cas9 delivery systems that may improve cancer therapeutics.